Morgan Stanley Initiates Coverage of Protein Design with 'Neutral'

Analyst Ian Somaiya says the stock has come under significant pressure after several recent clinical trial disappointments

Morgan Stanley initiated coverage of Protein Design (PDLI ) with netural.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.